 |
24 Diseases |  |
7 Trials |
|
7 Trials |  |
341 News |  |
| «1234 |
- || Symlin (pramlintide) / AstraZeneca
Enrollment open: A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone (clinicaltrials.gov) - Jun 6, 2018
P1, N=24, Recruiting, Sponsor: Adocia
Not yet recruiting --> Recruiting
- | Symlin (pramlintide) / AstraZeneca
New trial: Glucagon Counterregulation in Type 1 Diabetes (clinicaltrials.gov) - Jun 5, 2018
P=N/A, N=12, Recruiting, Sponsor: University of Virginia
- || Symlin (pramlintide) / AstraZeneca
New P1 trial: A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone (clinicaltrials.gov) - Apr 30, 2018
P1, N=24, Not yet recruiting, Sponsor: Adocia
- | Symlin (pramlintide) / AstraZeneca
Enrollment open: Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes (clinicaltrials.gov) - Jul 2, 2017
P2, N=28, Recruiting, Sponsor: McGill University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Symlin (pramlintide) / AstraZeneca
Journal: Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes. (Pubmed Central) - Jun 11, 2017
Not yet recruiting --> Recruiting Inhibition of glucagon and gastric emptying delaying reduced 2-hour prandial glucose excursions in T1D by delaying meal rate of glucose appearance.
- | Symlin (pramlintide) / AstraZeneca
Enrollment closed, Trial primary completion date, Surgery, Bariatric surgery: Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery (clinicaltrials.gov) - Apr 26, 2017
P4, N=22, Active, not recruiting, Sponsor: Joslin Diabetes Center
Inhibition of glucagon and gastric emptying delaying reduced 2-hour prandial glucose excursions in T1D by delaying meal rate of glucose appearance. Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Jul 2016
- | Symlin (pramlintide) / AstraZeneca, Byetta (exenatide) / AstraZeneca
Trial completion, Trial primary completion date: The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes (clinicaltrials.gov) - Apr 24, 2017
P4, N=16, Completed, Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Dec 2010 --> May 2011
- ||| Symlin (pramlintide) / AstraZeneca
Trial completion, Enrollment change: Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 9, 2016
P1, N=78, Completed, Sponsor: AstraZeneca
Recruiting --> Completed | Trial primary completion date: Dec 2010 --> May 2011 Active, not recruiting --> Completed | N=32 --> 78
- Symlin (pramlintide) / AstraZeneca
Trial primary completion date: Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes (clinicaltrials.gov) - Aug 31, 2016
P2, N=24, Not yet recruiting, Sponsor: McGill University
Active, not recruiting --> Completed | N=32 --> 78 Trial primary completion date: Dec 2017 --> Jun 2018
- Symlin (pramlintide) / AstraZeneca
Enrollment closed: Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 19, 2016
P1, N=32, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2017 --> Jun 2018 Recruiting --> Active, not recruiting
- Symlin (pramlintide) / AstraZeneca
New P2 trial: Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes (clinicaltrials.gov) - Jun 27, 2016
P2, N=24, Not yet recruiting, Sponsor: McGill University
- ||||||| Symlin (pramlintide) / AstraZeneca
Trial completion: Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 23, 2015
P3, N=190, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- Symlin (pramlintide) / AstraZeneca
Enrollment open: Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 26, 2015
P1, N=32, Recruiting, Sponsor: AstraZeneca
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- | Symlin (pramlintide) / AstraZeneca
New P1 trial: Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 17, 2015
P1, N=30, Not yet recruiting, Sponsor: AstraZeneca
- Symlin (pramlintide) / AstraZeneca, Byetta (exenatide) / AstraZeneca
Trial completion, Trial primary completion date: Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (clinicaltrials.gov) - Jun 23, 2015
P4, N=35, Completed, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2014
- ||||||| Symlin (pramlintide) / AstraZeneca
Trial completion: Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus (clinicaltrials.gov) - May 19, 2015
P3b, N=400, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2014 No longer recruiting --> Completed
- |||| Symlin (pramlintide) / AstraZeneca
Trial completion: A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects (clinicaltrials.gov) - Apr 8, 2015
P2b, N=400, Completed, Sponsor: AstraZeneca
No longer recruiting --> Completed No longer recruiting --> Completed
- | Symlin (pramlintide) / AstraZeneca
Trial completion, Enrollment change, Trial primary completion date: Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM (clinicaltrials.gov) - Oct 20, 2014
P1, N=32, Completed, Sponsor: AstraZeneca
No longer recruiting --> Completed Recruiting --> Completed | N=20 --> 32 | Trial primary completion date: Mar 2013 --> Sep 2013
- Symlin (pramlintide) / AstraZeneca
Trial termination: Pramlintide Combined With Model Predictive Control Algorithm (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=2, Terminated, Sponsor: University of Virginia
Recruiting --> Completed | N=20 --> 32 | Trial primary completion date: Mar 2013 --> Sep 2013 Recruiting --> Terminated; Modified study; created new study as a result of these modifications
- Symlin (pramlintide) / AstraZeneca
Enrollment change: Pramlintide Combined With Model Predictive Control Algorithm (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=2, Terminated, Sponsor: University of Virginia
Recruiting --> Terminated; Modified study; created new study as a result of these modifications N=18 --> 2
- Symlin (pramlintide) / AstraZeneca
Trial initiation date: Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Feb 17, 2014
P=N/A, N=9, Completed, Sponsor: University of Virginia
N=18 --> 2 Initiation date: Apr 2013 --> Jul 2013
- Symlin (pramlintide) / AstraZeneca
Enrollment change: Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Feb 17, 2014
P=N/A, N=9, Completed, Sponsor: University of Virginia
Initiation date: Apr 2013 --> Jul 2013 N=12 --> 9
- Symlin (pramlintide) / AstraZeneca
Trial completion: Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Feb 17, 2014
P=N/A, N=9, Completed, Sponsor: University of Virginia
N=12 --> 9 Not yet recruiting --> Completed
- | Symlin (pramlintide) / AstraZeneca
Enrollment open, Surgery, Bariatric surgery: Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery (clinicaltrials.gov) - Jun 18, 2013
P4, N=26, Recruiting, Sponsor: Joslin Diabetes Center
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- | Symlin (pramlintide) / AstraZeneca
New P4 trial, Surgery, Bariatric surgery: Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery (clinicaltrials.gov) - Apr 24, 2013
P4, N=26, Recruiting, Sponsor: Joslin Diabetes Center
- Symlin (pramlintide) / AstraZeneca
Enrollment open: Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM (clinicaltrials.gov) - Feb 25, 2013
P1, N=20, Recruiting, Sponsor: Amylin Pharmaceuticals, LLC.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Symlin (pramlintide) / AstraZeneca, Byetta (exenatide) / AstraZeneca
Enrollment closed: Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (clinicaltrials.gov) - Jan 24, 2013
P4, N=35, Active, not recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Symlin (pramlintide) / AstraZeneca, Byetta (exenatide) / AstraZeneca
Trial completion: Closedloop: Closed Loop System With Pramlintide Versus Exenatide (clinicaltrials.gov) - Jan 22, 2013
P1, N=13, Completed, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Symlin (pramlintide) / AstraZeneca
New P1 trial: Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM (clinicaltrials.gov) - Oct 14, 2012
P1, N=20, Recruiting, Sponsor: Amylin Pharmaceuticals, LLC.
- Symlin (pramlintide) / AstraZeneca
Trial withdrawal, Post-transplantation: Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=0, Withdrawn, Sponsor: University of Colorado, Denver
Recruiting --> Completed Enrolling by invitation --> Withdrawn
- Symlin (pramlintide) / AstraZeneca
Enrollment change, Post-transplantation: Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=0, Withdrawn, Sponsor: University of Colorado, Denver
Enrolling by invitation --> Withdrawn N=60 --> 0
- Symlin (pramlintide) / AstraZeneca
Enrollment change: Pramlintide in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=10, Completed, Sponsor: University of Colorado, Denver
N=60 --> 0 N=60 --> 10
- Symlin (pramlintide) / AstraZeneca
Trial completion: Pramlintide in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=10, Completed, Sponsor: University of Colorado, Denver
N=60 --> 10 Recruiting --> Completed
- Symlin (pramlintide) / AstraZeneca
Trial withdrawal: Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM (clinicaltrials.gov) - Jun 1, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Maryland
Recruiting --> Completed Recruiting --> Withdrawn
- Symlin (pramlintide) / AstraZeneca
Enrollment change: Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM (clinicaltrials.gov) - Jun 1, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Maryland
Recruiting --> Withdrawn N=24 --> 0
- Symlin (pramlintide) / AstraZeneca
Trial termination: Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port (clinicaltrials.gov) - Nov 15, 2011
P=N/A, N=31, Terminated, Sponsor: Texas Diabetes & Endocrinology, P.A.
N=24 --> 0 Recruiting --> Terminated; Lack of patient population
- Symlin (pramlintide) / AstraZeneca
Enrollment change: Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port (clinicaltrials.gov) - Nov 15, 2011
P=N/A, N=31, Terminated, Sponsor: Texas Diabetes & Endocrinology, P.A.
Recruiting --> Terminated; Lack of patient population N=50 --> 31
- | Symlin (pramlintide) / AstraZeneca
Enrollment closed: Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 12, 2011
P3, N=40, Active, not recruiting, Sponsor: Cheryl Rosenfeld, DO
N=50 --> 31 Recruiting --> Active, not recruiting
- |||| Symlin (pramlintide) / AstraZeneca
Trial completion: Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects (clinicaltrials.gov) - Oct 3, 2011
P2, N=636, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed